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Electrophysiological Studies in 
Thyroid Associated Orbitopathy: A 
Systematic Review
Tiara W. U. Iao1, Shi Song Rong  1,3, An Ni Ling1, Mårten E. Brelén1,2, Alvin Lerrmann Young1,2 
& Kelvin K. L. Chong  1,2
Dysthyroid optic neuropathy (DON) is the commonest cause of blindness in thyroid associated 
orbitopathy (TAO). While diagnosis remains clinical, objective tests for eyes with early or equivocal 
findings are lacking. Various electrophysiological studies (EPS) have been reported, yet the types 
and parameters useful for DON remain inconclusive. We performed a systematic literature search in 
MEDLINE, EMBASE and the Cochrane databases via the OVID platform up to August 20, 2017. 437 
records were identified for screening and 16 original studies (1327 eyes, 787 patients) were eligible 
for review. Pattern visual evoked potential (pVEP) was the most frequently studied EPS. Eyes of 
TAO patients with DON showed delayed P100 latencies, decreased P100 amplitudes or delayed N75 
latencies during pVEP, compared to those without or healthy controls. Due to study heterogeneity, 
no quantitative analysis was possible. This review highlights the most common type (pVEP) and 
useful parameters (P100 latency and amplitude) of EPS, and supports further research on them using 
standardized testing conditions.
Dysthyroid optic neuropathy (DON) is the commonest blinding complication affecting 4–8% of patients with 
thyroid associated orbitopathy (TAO), with an estimated annual incidence of 0.6–1.3 cases per 100,000 popu-
lation1,2. While exact mechanisms of DON remain elusive, apical compression by enlarged extraocular muscles 
and/or fat (crowding)3,4, ischemia due to increased retrobulbar pressure, mechanical stretch due to proptosis and 
perineural inflammation have been proposed5. Empirical treatments including surgical apical decompression, 
systemic steroids and orbital radiotherapy are often effective to restore vision. It is thus imperative to confirm 
diagnosis early to avoid irreversible visual loss and unnecessary treatments in alternative causes5. Ancillary tests, 
for example optical coherence tomography6, orbital imaging7 and electrophysiological studies (EPS), including 
visual evoked potential (VEP) and electroretinogram (ERG) were attempts to objectively assess the presence, 
predict the development and correlate with the severity of DON8–23. However, methodologies and results were 
heterogeneous across studies. In this systematic review, we studied published reports on EPS in DON.
Results
Characteristics of included studies. Our search yielded 768 reports from databases. After removing 331 
duplicated records, we studied 437 publications. Among them 415 studies were found to be irrelevant according 
to our eligibility criteria (see Methods below). For the remaining 22 studies, 8 reports were excluded: 1 report 
on a duplicated study population24, 1 case report25, 1 review article26, and 5 studies with irrelevant or insuffi-
cient results1,27–30. 2 additional studies were identified from manual search of references8,9. 16 studies were finally 
included for the systematic review (Fig. 1)8–23. No clinical trial was identified.
The pooled sample included 787 patients (1,327 eyes). The age of patients with DON ranged from 14 to 77 
years old13. VEP was used in 14 studies8–13,15–22. 3 studies tested pERG12,14,23. No study was found on flash or mul-
tifocal ERG (Table 1).
Phenotypic definition of subjects. Study populations were phenotypically defined as patients with DON, 
TAO, or healthy subjects. Clinical features of DON included optic disc swelling, relative afferent pupillary defect, 
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decreased visual acuity, impaired color vision, and visual field defect31. DON was considered “definite” if there 
was optic disc swelling or 2 of the four other clinical features above without alternative explanation in a patient 
with TAO32. Subclinical or “equivocal” DON was proposed by some as the presence of optic nerve dysfunction in 
TAO patients without the full-blown clinical features of DON15, often identified by abnormal electrophysiological 
changes8,12,13,16,18,22.
Flash VEP (fVEP) in TAO & DON. Only 2 earlier studies reported use of fVEP in TAO and DON patients 
(Tables 2 and 3)9,11. Alteration in P2 amplitude was reported in clinically evident DON11. Tsaloumas et al. found 
significantly smaller P2 amplitude in DON eyes which improved either after orbital decompressions (6.83 ± 0.92 
vs. 13.12 ± 1.65 µV; P < 0.05) or 2 weeks of high-dose systemic steroids (7.00 ± 1.10 vs. 9.61 ± 1.43 µV; P < 0.0511. 
However, treatment-related improvement was not shown in Setala’s study after decompression or radiotherapy9.
Pattern VEP (pVEP) in TAO & DON. Comparison of pVEP results in DON, TAO, and normal con-
trols. P100 latency, P100 amplitude, and N75 latency were compared between DON and normal controls in 3 
studies10,11,17. An increase in P100 latency of patients with DON was reported by Shawkat et al. (115.2 ± 5.7 vs. 
103.2 ± 4.3 ms, P = 0.0005)10, Tsaloumas et al. (129.2 ± 7.1 vs. 108.2 ± 1.2 ms, P < 0.005)11, and Ambrosio et al. 
(P < 0.0001)17. A decrease in P100 amplitude was found in eyes with DON compared to control by Tsaloumas et al. 
(3.67 ± 0.81 vs. 8.97 ± 0.59 µV, P < 0.001)11 and Ambrosio et al. (P < 0.0001)17.
Comparisons between TAO eyes with or without DON were reported in 3 studies10,11,15. Significant increases 
in P100 latency in eyes with DON were shown by Shawkat et al. (115.2 ± 5.7 vs. 110.3 ± 5.1 ms, P = 0.043)10, 
Tsaloumas et al. (129.2 ± 7.13 vs. 111 ± 1.86 ms, P < 0.005)11, and Rutecka-Debniak et al. (124.4 ± 15.4 vs. 
114.9 ± 11.2 ms, P = 0.05)15. Significant decreases in P100 amplitude in DON patients were reported by Shawkat 
et al. (11.9 ± 6.4 vs. 21.2 ± 9.7 µV, P = 0.018)10 and Tsaloumas et al. (3.67 ± 0.81 vs. 8.55 ± 0.73 µV, P < 0.001)11. 
Moreover, the mean N75 latency of eyes with DON was also increased (90.0 ± 17.9 vs. 80.3 ± 14.7 ms, P = 0.01)15.
Five studies reported significant increases in P100 and N75 latencies comparing eyes from TAO patients with-
out DON to healthy eyes (Table 2)8,12,13,16,18. Wijngaarde et al. first reported significant increase in P100 latency of 
TAO to healthy eyes (P < 0.01)8. Spadea et al. (126.7 ± 10.7 vs. 118.5 ± 5.7 ms, P < 0.05)12, Salvi et al. (105.6 ± 0.5 
vs. 102.0 ± 0.5 ms, P < 0.001)13, Acaroglu et al. (122.0 ± 14.4 vs. 105.9 ± 7.7 ms, P = 0.0004)16, and Pawlowski et 
al. (106.2 ± 4.4 vs. 102.4 ± 2.7 ms, P < 0.01) also found increased P100 latencies in eyes from TAO subjects with-
out clinical evidence of DON when compared with controls18. In addition, Pawlowski et al. found an increase in 
N75 latency (79.0 ± 3.7 vs. 73.9 ± 2.8 ms, P < 0.001)19, while Spadea et al. showed a decrease in P100 amplitude 
Figure 1. Flowchart of the literature search and study selection process.
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Author (year) Country/region Study Design EPS tested ISCEV
Sample 
size
TAO Age 
range (mean)
DON Age 
range (mean) Subgroups Outcomes
1 Wijngaarde et al.8 The Netherlands Prospective case series pVEP ✗ 53 n.a. — TAO/Control
Correlation between 
P100 (latency) and VA
2 Setala et al.9 Finland Prospective case series fVEP ✗ 31 28–66 — TAO
The differences in N60 
& P120 (amplitude & 
latency) before and after 
TAO treatment
3 Shawkat et al.10 England
Prospective 
case-control 
study
pVEP ✗ 20 37–62 (47.3) 37–62 (47.3) DON/TAO/Control
The differences in P100 
(amplitude & latency) 
among DON, TAO and 
control
4 Tsaloumas et al.11 UK Retrospective case series fVEP, pVEP ✗ 43 23–68 (45.1) 26–73 (49.1)
DON/TAO/
Control
The differences in P2 
(amplitude & latency) 
among DON, TAO and 
control; The differences 
in P2 (amplitude & 
latency) before and after 
DON treatment
5 Spadea et al.12 Italy Prospective case series pVEP, pERG ✗ 49 (57.2) — TAO/Control
The differences in P100 
(amplitude & latency) 
between TAO and 
control
6 Salvi et al.13 Italy Retrospective case series pVEP ✗ 117 14–77 (45.3) — TAO/Control
The differences in P100 
(amplitude & latency) 
between TAO and 
control
7 Genovesi-Ebert et al.14 Italy Prospective case series pERG ✗ 44 (51.9) — TAO/Control
The significant difference 
in amplitude between 
TAO and control
8 Rutecka-Debniak et al.15 Poland Prospective case series pVEP ✗ 110 18–74 18–74 DON/TAO
The differences in N75 & 
P100 (latencies) between 
DON and TAO; The 
differences in N75 & 
P100 (latencies) before 
and after DON & TAO 
treatment
9 Acaroglu et al.16 Turkey Prospective case series pVEP ✗ 31 20–65 (41.7) — TAO/Control
The difference in P100 
(latency) between TAO 
and control; Correlation 
between P100 (latency) 
and CAS
10 Ambrosio et al.17 Italy
Prospective 
case-control 
study
pVEP ✗ 63 (36.3) (42.5) DON/TAO/Control
The differences in P100 
(amplitude & latency) 
between DON and 
control
11 Pawlowski et al.18 Poland Prospective case series pVEP ✓2004
49 27 35.6 ± 11.3 — TAO/Control
The differences in 
N75 (latency) & P100 
(amplitude & latency) 
between TAO and 
control; Correlation 
between N75 & P100 
(latencies) and IOP & 
degree of proptosis
12 Liao et al.19 China Taiwan Retrospective case series pVEP n.a. 22 — 30–76 (58.4) DON
The differences in P100 
(latency) before and after 
DON treatment
13 Wei et al.20 China Taiwan Prospective case series pVEP n.a. 76 22–79 (46.7) — TAO
Correlation between 
P100 (latency) and VA, 
degree of proptosis, color 
test, visual field test, 
OCT and extraocular 
muscles measurements
14 Lipski et al.21 Germany Retrospective case series pVEP ✓2004
49 15 — 43–76 (55) DON
The differences in P100 
(amplitude & latency) 
before and after DON 
treatment
15 Perez-Rico et al.22 Spain Prospective case series mfVEP — 65 47.5 ± 11.5 — TAO/Control
The difference in latency 
between TAO and 
control
16 Pawlowski et al.23 Poland
Prospective 
case-control 
study
pERG ✓201241 21 24–55 (36) — TAO/Control
The difference in P50 
amplitude between TAO 
and control
Table 1. Characteristics of included studies in the systematic review. DON = dysthyroid optic neuropathy; 
EPS = electrophysiological studies; fVEP = flash visual evoked potential; ISCEV = International Society for the 
Clinical Electrophysiology of Vision Standard; mfVEP = multifocal visual evoked potential; n.a. = not available; 
OCT = optical coherence tomography; pERG = pattern electroretinography; pVEP = pattern visual evoked 
potential; TAO = thyroid associated orbitopathy; VA = visual acuity.
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(3.47 ± 3.81 vs. 9.78 ± 4.26 µV, P < 0.05) in TAO patients comparing to normal subjects12. However, the differ-
ences between eyes from TAO patients and normal controls in N75 and P100 latencies were insignificant in other 
studies (Shawkat et al.10 and Tsaloumas et al.11). While these TAO patients did not show clinical evidence of DON, 
abnormal pVEP in particular prolonged P100 latencies may present electrophysiological evidence of early or 
subclinical optic nerve dysfunction in TAO patients.
Correlation of pVEP latencies with clinical parameters. Four studies investigated correlation between 
pVEP latencies and clinical parameters (Table 4)8,16,18,20. Wijngaarde et al. reported a mild but significant correla-
tion (r = 0.27, P value not available) of P100 latency with Snellen visual acuity8, while Wei et al. reported a similar 
degree of correlation without statistical significance (r = 0.278, P > 0.05) using LogMAR visual acuity20. In the 
latter study, correlation of P100 latency was moderate and statistically significant with total cross-sectional areas 
of all extraocular rectus muscles (EOM-A) (r = 0.496, P < 0.01); moderate but insignificant with ratio between 
the total cross-sectional area of all extraocular rectus muscles and the orbital area (r = 0.482, P > 0.05), mild and 
insignificant with total error of 100-hue color sensation (r = 0.363, P > 0.05) and with mean deviation of retinal 
sensitivity (MD) in perimetry (r = −0.342, P > 0.05). On the other hand, the correlation between peripapillary 
nerve fiber layer thickness and degree of exophthalmos with P100 latency was insignificant20. Acaroglu et al. 
reported a mild but significant correlation between the disease activity (clinical activity score) and P100 latency 
(r = 0.364, P = 0.04)16.
The correlation between degree of exophthalmos and pVEP varied among studies. Pawlowski et al. reported 
a moderate and significant correlation between degree of proptosis and N75 latency (r = 0.51, P < 0.01) but not 
with p100 latency18. On the other hand, Wijngaarde et al. described a mild correlation coefficient between degree 
of proptosis and P100 latency (r and P value not available)8, while Wei et al. reported poor and insignificant cor-
relation (r = −0.126, P value not available)20.
pVEP after treatments. Four studies reported the pVEP results before and after treatments including 
high-dose steroids, orbital radiotherapy and/or decompression (Table 3)11,15,19,21. While treatment strategies 
varied, increase in p100 amplitude and/or decrease in p100 latency post-treatment were generally observed. 
More improvements were observed in eyes with DON than those without. Three studies reported more than 
10% decrease in P100 latency after treatment of DON. Tsaloumas et al. reported a significant decrease (from 
129.2 ± 7.13 to 114.0 ± 4.47 ms, P < 0.01)11, and so did Rutecka-Debniak et al. (from 126.0 ± 15.9 to 108.0 ± 5.3 
ms, P = 0.01)15 and Liao et al. (from 134.8 ± 22.1 to 107.3 ± 4.0 ms, P < 0.001)19. Rutecka-Debniak et al. also 
No. Author (year)
Age range (mean) Sample size (eyes)
VEP outcome
Mean ± SD
DON TAO Control DON TAO Control DON TAO Control
fVEP
4 Tsaloumas et al.11 26–73 (49.1) 23–68 (45.1) 22–68 (46.1) 8 (13) 15 (30) 20 (40) P2 amplitude (µV) 6.83 ± 0.92†‡ 12.40 ± 1.05 11.72 ± 1.16
P2 latency (ms) 112.0 ± 4.46 110.1 ± 2.65 109.6 ± 2.08
pVEP
1 Wijngaarde et al.8 n.a. n.a. 33 (66) 20 (40) P100 amplitude (µV) n.a. Data n.a. n.a.
P100 latency (ms) n.a. Data n.a‡ n.a.
3 Shawkat et al.10 37–62 (47.3) 37–62 (47.3) 37–62 (47.3) 10 (10) 10 (10) 10 (10) P100 amplitude (µV) 11.9 ± 6.4* 21.2 ± 9.7 Data n.a.
P100 latency (ms) 115.2 ± 5.7*§ 110.3 ± 5.1 103.2 ± 4.3
4 Tsaloumas et al.11 26–73 (49.1) 23–68 (45.1) 22–68 (46.1) 8 (13) 15 (30) 20 (40) P100 amplitude (µV) 3.67 ± 0.81†§ 8.55 ± 0.73 8.97 ± 0.59
P100 latency (ms) 129.2 ± 7.13*‡ 111 ± 1.86 108.2 ± 1.19
5 Spadea et al.12 (57.2) 41–60 9 (18) 40 (40) P100 amplitude (µV) n.a. 3.47 ± 3.81‡ 9.78 ± 4.26
P100 latency (ms) n.a. 126.7 ± 10.7 ‡ 118.5 ± 5.7
6 Salvi et al.13 14–77 (45.3) 14–73 (41.8) 88 (172) 29 (56) P100 amplitude (µV) n.a. 10.2 ± 0.3 11.3 ± 0.6
P100 latency (ms) n.a. 105.6 ± 0.5§ 102.0 ± 0.5
8 Rutecka-Debniak 
et al.15
18–74 18–74 18–74 12 (21) 13 (26) N75 latency (ms) 90.0 ± 17.9* 80.3 ± 14.7 n.a.
P100 latency (ms) 124.4 ± 15.4* 114.9 ± 11.2 n.a.
9 Acaroglu et al.16 20–65 (41.7) 23–65 (42.3) 16 (32) 15 (30) P100 latency (ms) n.a. 122.0 ± 14.4§ 105.9 ± 7.7
10 Ambrosio et al.17 (42.5) (44.3) 14 (28) 20 (40) P100 amplitude (µV) Data n.a§ n.a. n.a.
P100 latency (ms) Data n.a§ n.a. n.a.
11 Pawlowski et al.18 (35.6) (28.6) 15 (30) 12 (24) N75 latency (ms) n.a. 79.0 ± 3.7§ 73.9 ± 2.8
P100 amplitude (µV) n.a. 7.3 ± 3.5 6.5 ± 2.5
P100 latency (ms) n.a. 106.2 ± 4.4‡ 102.4 ± 2.7
13 Wei et al.20 22–79 (46.7) 76 (151) P100 latency (ms) n.a. 103.7 ± 10.0 n.a.
mfVEP
15 Perez-Rico et al.22 (47.5) (48.1) 34 (65) 31 (62) mfVEP latency (ms) n.a. 6.57 ± 1.90 ‡ 2.12 ± 1.72
Table 2. Summary outcomes of observational case series and case-control studies on the use of VEP in DON/
TAO. DON = dysthyroid optic neuropathy; fVEP = flash visual evoked potential; mfVEP = multifocal visual 
evoked potential; ms = millisecond; n.a. = not available; pERG = pattern electroretinography; pVEP = pattern 
visual evoked potential; TAO = thyroid associated orbitopathy; VEP = visual evoked potential; µV = microvolts. 
*P < 0.05 compared to TAO without DON, †P < 0.001 compared to TAO without DON, ‡P < 0.05 compared to 
Control, §P < 0.001 compared to Control.
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reported a significant decrease in N75 latency in eyes with DON after treatment (from 93.3 ± 18.7 to 78.8 ± 7.7 
ms, P = 0.01)15. Significant increase in P100 amplitude over 50% was reported by Tsaloumas et al. after decom-
pression (from 3.67 ± 0.81 to 6.50 ± 0.67 µV, P < 0.01) and high-dose steroids treatment (from 5.30 ± 0.89 to 
8.06 ± 0.80 µV, P < 0.01)11. Lipski et al. also reported significant increase in P100 amplitude after bony orbital 
decompression (from 4.45 ± 2.3 to 8.8 ± 6.32 µV, P < 0.05)21.
In TAO eyes with no clinical evidence of DON but prolonged P100 latency, Rutecka-Debniak et al. 
reported a significant decrease after treatment (from 114.8 ± 12.6 to 107.3 ± 13.2 ms, P = 0.05)15. There was no 
post-treatment change in TAO eyes with normal pre-treatment VEP.
Multifocal VEP (mfVEP) in TAO. In 2012, Perez-Rico et al. first reported the use of mfVEP in TAO patients 
without DON22. There was a significant increase in mean latency in TAO group compared to age-matched 
control (2.12 ± 1.72 vs. 6.57 ± 1.90 ms, P < 0.05) and 23 eyes (35.4%) had abnormal mfVEP amplitude and/or 
latency. By interocular comparison, 12.3% of TAO eyes showed decreased amplitude and 13.8% of them showed 
increased latency. Visual acuity was significantly related to mfVEP amplitude changes (mean difference = −0.104, 
P = 0.018), while intraocular pressure measured at upgaze was significantly related to mfVEP latency changes 
(mean difference = 2.595, P = 0.028). No statistically significant relationship was observed between mfVEP 
parameters and standard automated perimetry results or nerve fiber layer thickness measured on optical coher-
ence tomography22.
Electroretinography (ERG) in TAO. Comparing TAO eyes with controls, Spadea et al. found significant 
decreases in amplitudes for both P50 (1.17 ± 0.58 vs. 1.74 ± 0.50 µV, P < 0.05) and N95 (1.71 ± 1.10 vs. 2.37 ± 0.59 
µV, P < 0.05)12. No significant difference was found in latency12. Genovesi-Ebert et al. reported significantly 
No. Author (year)
Definition 
of cases
Age 
group Sample size (eyes) Treatment VEP outcome
Reported values (mean ± SD)
Pre-treatment Post-treatment
fVEP
2
Setala et al.9 TAO 49–66 (55.8) 7 (13) Decompression N60 amplitude (µV) 15.8 ± 6.1 13.8 ± 6.9
N60 latency (ms) 83.1 ± 21.6 81.9 ± 16.6
P120 amplitude (µV) 8.0 ± 4.0 7.7 ± 4.2
P120 latency (ms) 130.0 ± 21.3 129.4 ± 20.5
TAO 50–64 (55.3) 3 (6) Irradiation N60 amplitude (µV) 16.8 ± 5.7 13.8 ± 6.0
N60 latency (ms) 80.9 ± 7.0 87.5 ± 7.4
P120 amplitude (µV) 8.5 ± 8.3 6.7 ± 7.3
P120 latency (ms) 114.8 ± 14.8 123.2 ± 17.0
4
Tsaloumas et al.11 DON 26–73 (49.1) 6 Decompression P2 amplitude (µV) 6.83 ± 0.92 13.12 ± 1.65*
P2 latency (ms) 112.0 ± 4.46 106.7 ± 3.34
DON 26–73 (49.1) 10
2 weeks High-
dose steroids P2 amplitude (µV) 7.00 ± 1.10 9.61 ± 1.43*
P2 latency (ms) 118.4 ± 5.79 108.3 ± 5.47
pVEP
4
Tsaloumas et al.11 DON 26–73 (49.1) 6 Decompression P100 amplitude (µV) 3.67 ± 0.81 6.50 ± 0.67*
P100 latency (ms) 129.2 ± 7.13 114.0 ± 4.47*
DON 26–73 (49.1) 10
2 weeks High-
dose steroids P100 amplitude (µV) 5.30 ± 0.89 8.06 ± 0.80*
P100 latency (ms) 116.1 ± 4.71 111.4 ± 4.89
8
Rutecka-
Debniak et al.15 DON 18–74 12 (21) Unspecified N75 latency (ms) 93.3 ± 18.7 78.8 ± 7.7*
P100 latency (ms) 126.0 ± 15.9 108.0 ± 5.3*
TAO 18–74 13 (18) Unspecified N75 latency (ms) 81.7 ± 16.6 74.6 ± 7.9
P100 latency (ms) 114.8 ± 12.6 107.3 ± 13.2*
12 Liao et al.19 DON 30–76 (58.4) 22 (38) Decompression P100 latency (ms) 134.8 ± 22.1 107.3 ± 4.0
†
14
Lipski et al.21 DON 43–76 (55) 15 (30) Decompression P100 amplitude (µV) 4.45 ± 2.3 8.8 ± 6.32*
P100 latency (ms) 130.2 ± 11.22 127.8 ± 12.07
Table 3. Summary outcomes of longitudinal case series comparing VEP changes before and after treatment 
for DON/TAO. DON = dysthyroid optic neuropathy; fVEP = flash visual evoked potential; ms = millisecond; 
No. = number; pVEP = pattern visual evoked potential; TAO = thyroid associated orbitopathy; VEP = visual 
evoked potential; µV = microvolts. *P < 0.05 compared to pre-treatment, †P < 0.001 compared to pre-
treatment.
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smaller (P < 0.0001) pERG amplitude in TAO eyes without providing numerical results14. They also described a 
negative correlation of pERG amplitude with optic nerve diameter measured by ultrasonography. Pawlowski et 
al. reported significant decrease in P50 amplitude in TAO eyes (2.04 ± 0.99 vs. 2.69 ± 0.88 µV, P < 0.05) but not in 
N95 amplitude or latencies23. 3 studies reported drop in P50 amplitude12,14,23, with statistical significance shown 
by Spadea et al. and Pawlowski et al.12,23.
Assessment of the quality of study and grading of clinical recommendation. The 12 studies on 
VEPs were assessed according to the NOS (Newcastle-Ottawa Scale) quality assessment of case-control studies33 
(Table 5). The study with best quality was carried out by Tsaloumas et al. in 199411. Clinical recommendation of 
EPS in detecting and monitoring visual dysfunction in TAO was rated according to the American Academy of 
Ophthalmology on preparing Preferred Practice Pattern (PPP) guidelines (Table 6)34. pVEP was given level A 
importance in application and level II in strength of evidence.
Discussion
Clinical features of DON may include impaired visual acuity and color vision, visual field, afferent and rela-
tive affect pupillary defect (APD/RAPD), optic disc hyperemia or swelling5,31,35. In practice, these features rarely 
co-exist while ocular co-morbidities often confound with clinical assessment35. The European Group on Graves’ 
Orbitopathy (EUGOGO) was the first to propose that the presence of optic disc swelling alone or any other 
two of the above abnormalities without an alternative explanation suggested the presence of DON in any TAO 
patient35,36. Among the 94 eyes recruited, impaired visual acuity (<20/40), color vision, visual field defects, relative 
afferent pupillary defect and optic disc swelling were present in only 73%, 77%, 71%, 45%, and 56% of eyes sub-
sequently diagnosed to have “definite DON”. On the other hand, these abnormalities were also found in 32%, 7%, 
13%, 0% and 5% of eyes subsequently diagnosed to have “no DON”. These results implied that none of the individ-
ual findings of optic nerve dysfunction was found to be sensitive or specific enough to diagnose or exclude DON. 
Proptosis or increased clinical activity scores (≥3/7) were absent in more than one-third of eyes with “definite” 
DON35. Despite its serious visual consequences, no widespread consensus on the diagnostic criteria of DON 
is available to date. The challenge in diagnosing DON at its early stage or in patients with ocular comorbidities 
remains.
Electrophysiological studies (EPS), including visual evoked potential (VEP) and electroretinogram (ERG) 
were adopted to provide objective evaluation and correlation with the presence and/or severity of DON. VEP 
refers to the electrophysiological signals extracted from visual cortex during visual stimulation over the retina37. 
Any disturbance along the visual pathway or visual cortex results in VEP abnormalities (decrease in amplitude or 
increase in latency). It was first reported in 1972 by Halliday et al. to assess optic neuritis38. Subsequently it was 
used in patients with DON in 1980 by Wijngaarde et al.8. Three types of VEP have been used: flash VEP (fVEP), 
pattern VEP (pVEP), and multifocal VEP (mfVEP) (Table 7). fVEP uses a diffuse flash stimulating the entire ret-
ina for a mass response. Therefore, localized abnormal response may be averaged out and left undetected. pVEP 
uses checkerboard pattern reversal simulation covering the central 15° visual field. The major components of 
pVEP are a large positive wave at peak latency of about 100 milliseconds (P100) and a negative wave peaking at 
70 milliseconds (N70). Any delay in P100 latency or decrease in amplitude measured from N70 to P100 suggests 
the presence of optic neuropathy37. Since the first report on pVEP in assessing visual function in TAO patients 
by Wijngaarde et al. in ref.8,9 other studies were published comparing the use of pVEP in TAO patients with or 
No. Author (year)
Definition of 
subjects
Age range 
(mean)
Sample size 
(eyes)
VEP 
latency
Clinical 
measurement
Correlation
P value r
1 Wijngaarde et al.8 TAO n/a 66 P100 VA Significant 0.270
9 Acaroglu et al.16 TAO 20–65 (41.7) 32 P100 CAS 0.0406 0.364
11 Pawlowski et al.18 TAO (35.6) 30 N75 Exophthalmos <0.01 0.510
P100 IOP Insignificant —
P100 Exophthalmos Insignificant —
13 Wei et al.20 TAO 22–79 (46.7) 151 P100 logMAR <0.1 0.278
P100 Exophthalmos Insignificant −0.126
P100 total error <0.1 0.363
P100 MD <0.1 −0.342
P100 ON Insignificant −0.055
P100 M/O ratio <0.1 0.482
P100 EOM-A <0.01 0.496
Table 4. Correlations between pVEP latencies and clinical measurements of DON/TAO. CAS = clinical activity 
score; DON = dysthyroid optic neuropathy; EOM-A = cross-sectional area of all extraocular rectus muscles; 
IOP = intraocular pressure; logMAR = logarithm of the minimal angle of resolution; MD = mean deviation of 
retinal sensitivity; M/O ratio = ratio between the cross-sectional area of all extraocular rectus muscles and the 
orbital area; No. = number; ON = peripapillary nerve fiber thickness; pVEP = pattern visual evoked potential; 
r = correlation coefficient; TAO = thyroid associated orbitopathy; total error = total error of 100-hue color 
sensation; VA = visual acuity; VEP = visual evoked potential.
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without DON (Table 2). mfVEP records signals from multiple stimuli given simultaneously across 20° to 25° of 
the central visual field enabling assessment of small local defects39.
ERG records the electrical response of the retina upon light stimulation by various types of corneal electrodes. 
ERG is widely used in retinal disorders but rarely in TAO40. Pattern electroretinogram (pERG) uses reversing 
black and white checkerboard stimulus to collect signals from inner retina and indirectly measure retinal gan-
glion cell function. Commonly used parameters of pERG include a prominent positive wave at approximately 
50 millisecond (P50) and a larger negative wave at about 95 millisecond (N95)41. pERG was used for evaluating 
early ganglion cell dysfunction in glaucoma patients since 1980s42,43. pERG alteration was also reported in animal 
models of optic nerve transection during retrograde degeneration of retinal ganglion cells44,45. In clinical practice, 
combined interpretation of pVEP and pERG helps to differentiate retinal (abnormal pVEP and pERG) from optic 
nerve disorders (abnormal pVEP and normal pERG)46.
Here we report the first systematic review on the use of EPS in DON. pVEP has been the most widely reported 
EPS in DON. Case-control studies reported significant differences of pVEP parameters among eyes with DON, 
TAO only and from controls8,10–13,15–18,22. Prolonged P100 latency was found comparing either eyes with DON to 
eyes without from TAO patients or eyes from TAO patients to control. P100 latency correlated with visual acuity, 
clinical activity score, color vision, visual field, and orbital imaging parameters8,20. Significant improvement in 
pVEPs were found in patients after successful treatment of DON11,15,19,21.
We acknowledge insufficient evidence to support the use of pVEP as part of the diagnostic criteria of DON 
due to its limited availability and inherent variability. To improve generalizability for meta-analysis, future studies 
should adopt testing protocols by the International Society for the Clinical Electrophysiology of Vision (ISCEV) 
standards37,41,47–49, include age and/or gender-specific reference ranges, post-treatment follow-up results and all 
clinical parameters recommended by the EUGOGO5,31,35,37. Longitudinal follow-up of pVEP on TAO patients 
with equivocal or early clinical features of DON may shed insight on the natural history, treatment response and 
clincal implication on the evolving entity of “subclinical” DON.
In conclusion, pVEP was the most studied EPS in DON. Latency and amplitude of P100 were shown to be 
promising for the diagnosis and monitoring of DON. Future studies on pVEP using standardized settings will be 
required to fully evaluate its diagnostic accuracy and clinical utility in the management of DON.
Author
Newcastle-Ottawa Quality Assessment Scale (NOS) for Case-control Study33
Selection Comparability Exposure
Total 
Stars(Year of Publication)
Case 
Definition
Representativeness 
of Cases
Selection 
of 
Controls
Definition 
of Controls
Comparability 
of cases and 
controls (a)
Comparability 
of cases and 
controls (b)
Ascertainment 
of exposure
Same method of 
ascertainment
Non-
Response 
rate
Wijngaarde et al.8 − − − − − − − * n.a. 1
Shawkat et al.10 − − − − * * − * n.a. 3
Tsaloumas et al.11 * * * * * * − * n.a. 7
Spadea et al.12 * − − * * − − * n.a. 4
Salvi et al.13 − * − * * − − * n.a. 4
Genovesi-Ebert et al.14 − − − − * − − * n.a. 2
Rutecka-Debniak et al.15 − − − * − − − * n.a. 2
Acaroglu et al.16 * − − * * * − * n.a. 5
Ambrosio et al.17 * − − * * − − * n.a. 4
Pawlowski et al.18 * − * * * * − * n.a. 6
Perez-Rico et al.22 * * − * * * − * n.a. 6
Pawlowski et al.23 * − * * * * − * n.a. 6
Table 5. Quality Assessment for Included Case-control Studies. *A star is awarded when the study meets the 
quality standard of an item. Details of the requirements of each item can be found in NOS for Case-control 
Study checklist33. n.a.: not available. Note: A study may be awarded a maximum of one star for each item within 
the Selection and Exposure categories. A maximum of two stars may be given for Comparability. A score of ≥7 
stars is indicative of a high-quality study33.
Clinical care Recommendation Evidence rating
Detecting and monitoring visual dysfunction in TAO The use of fVEP [B:II]
Detecting and monitoring visual dysfunction in TAO The use of pVEP [A:II]
Detecting and monitoring visual dysfunction in TAO The use of mfVEP [B:II]
Detecting and monitoring visual dysfunction in TAO The use of pERG [C:II]
Table 6. Clinical recommendation of VEP or ERG in detecting visual dysfunction in TAO. A = most important 
application; B = moderately important application; C = relevant but not critical application; II = well-designed 
cohort or case-control analytic studies, preferably from more than one center, or multiple-time series with or 
without the intervention.
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Methods
Literature search. Literature search was performed in MEDLINE, EMBASE, and the Cochrane databases 
via Ovid platform. We formulated sensitive search strategies using the Boolean logic and search terms with con-
trolled vocabularies (Medical Subject Heading terms): (“thyroid associated” OR “endocrine” OR “dysthyroid” OR 
“Graves”) AND (“orbitopathy[ies]” OR “ophthalmopathy[ies]”) OR (“ophthalmic Graves’ disease”) in combina-
tion with “optic neuropathy(ies)” (Table 8). The search was supplemented by manual screening of the reference 
lists of the relevant articles and reviews. Language filter was not applied in the search. We identified records pub-
lished from January 1st, 1977 to August 20th, 2017.
Eligibility criteria. Studies were included in the systematic review according to the following criteria: (1) 
studies that used electrophysiological tests (e.g. VEP or ERG) to evaluate optic nerve dysfunction in patients with 
TAO or DON; and (2) studies can be observational case series, case-control study, cohort study, interventional 
case series, and clinical trials. Animal studies, case reports, reviews, abstracts, conference proceedings, and edi-
torials were excluded.
Assessment of the quality of study and level of evidence. NOS (Newcastle-Ottawa Scale)33 was 
adopted to evaluate the quality of the case-control studies. The clinical recommendation of VEP or ERG 
in detecting and monitoring visual dysfunction in TAO were rated from 2 aspects, “importance to the care 
process” and “the strength of evidence in the available literature”, according to the American Academy of 
Ophthalmology on preparing Preferred Practice Pattern (PPP) guidelines34. “Importance to the care process” 
represents the value of this application to improve the quality of the patient’s care in a meaningful way. Level 
A indicates the most important; level B indicates moderately important and level C indicates relevant but 
not critical application. “Strength of evidence” was rated in 3 levels. Level I includes evidence obtained from 
at least one properly conducted, well-designed, randomized, controlled trial. It also includes meta-analysis 
EPS test Key features No. of studies Reported parameters Reference
Visual evoked potential
fVEP Diffuse flash stimulus, full-field, one response, examine whole visual pathway 2
amplitude & latency of 
P2, N60, P120 9,11
pVEP Checkerboard pattern reversal stimulus, central≥15° field, one response, examine whole visual pathway 12
amplitude & latency of 
N75, P100 8,10–13,15–21
mfVEP
16 checks times 60 sectors stimulus, central 20 to 25° field, 60 
topographic responses, examine whole visual pathway in 60 
sectors
1 amplitude & latency 22
Electroretinography
fERG Diffuse flash stimulus, full-field, one response, examine retinal cells 0 n/a n/a
pERG Checkerboard pattern reversal stimulus, central 15° field, one response, examine retinal cells 3
amplitude & latency of 
N35-P50, P50-N95 12,14,23
mfERG 103 scaled hexagons stimulus, central 25° field, 103 topographic responses, examine retinal cells in 103 sectors 0 n/a n/a
Table 7. Features of included studies. EPS = electrophysiological studies; fVEP = flash visual evoked potential; 
pVEP = pattern visual evoked potential; mfVEP = multifocal visual evoked potential; pERG = pattern 
electroretinography; mfERG = multifocal electroretinography; No. = number; n/a. = not applicable.
No. Search terms
1 ((thyroid associated or thyroid-associated) and (orbitopathy or orbitopathies or ophthalmopathy or ophthalmopathies)).mp.
2 (endocrine and (orbitopathy or orbitopathies or ophthalmopathy or ophthalmopathies or exophthalmos)).mp.
3 ophthalmic Graves disease.mp.
4 (thyroid and (orbitopathy or orbitopathies or ophthalmopathy or ophthalmopathies)).mp.
5 (Graves adj1 (orbitopathy or orbitopathies or ophthalmopathy or ophthalmopathies)).mp.
6 (dysthyroid and (orbitopathy or orbitopathies or ophthalmopathy or ophthalmopathies)).mp.
7 1 or 2 or 3 or 4 or 5 or 6
8 (optic adj1 (neuropathy or neuropathies)).mp.
9 (optic adj1 nerve adj1 (disease or disorder)).mp.
10 8 or 9
11 7 and 10
12 (dysthyroid adj1 (optic adj1 (neuropathy or neuropathies))).mp.
13 11 or 12
Table 8. Search strategies used in MEDLINE and EMBASE.
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of randomized controlled trials. Level II includes well-designed controlled trials without randomization, 
well-designed cohort or case-control analytic studies, preferably from more than one center, or multiple-time 
series with or without the intervention. Level III includes evidence obtained from descriptive studies or case 
reports.
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